The object of this work was to assess the effectiveness of intermittent prophylaxis with clotrimazole 500 mg vaginal tablets in managing patients with recurrent vaginal candidosis. We intended to maintain the women free of symptoms and signs for 12 months by treating them, as required if they experienced clinical relapse, with three successive prophylactic regimens.
Most women with vaginal candidosis respond well to local antifungal treatment. In some, however, the infection is recurrent, often developing month after month, whereas others have persistent symptoms that fail to respond to treatment. Antifungal prophylaxis is a potential method of controlling the condition, and the newer single dose topical formulations of azole antifungal drugs, which have proved effective against acute vaginal candidosis,'2 permit much simpler prophylactic regimens to be devised than was possible in the past.
The object of this work was to assess the effectiveness of intermittent prophylaxis with clotrimazole 500 mg vaginal tablets in managing patients with recurrent vaginal candidosis. We intended to maintain the women free of symptoms and signs for 12 months by treating them, as required if they experienced clinical relapse, with three successive prophylactic regimens.
Patients and methods
To be eligible for admission to this trial patients had to have had at least three documented episodes ofvaginal At each visit Gram stained vaginal smears were examined at the clinics, and vaginal swabs were sent for culture. The swabs were inoculated on to glucose peptone agar plates, which were incubated at 37°C for 48 hours. Isolates were identified as Candida albicans on the basis of germ tube formation in horse serum after incubation at 37°C for three hours. Germ tube negative isolates were identified with the API 20C AUX yeast identification system (API Laboratory Products, Basingstoke, England).
Two thirds ofthe patients were first treated with one clotrimazole 500 mg vaginal tablet and the remainder were given six clotrimazole 100 mg vaginal tablets. Patients with vulvitis were also given clotrimazole cream. No attempt was made to treat their sexual partners. Patients were instructed to return to the clinic one week after completing their initial course of treatment, at which time women who had failed to respond were given further treatment with six clotrimazole 100 mg vaginal tablets. 335
Once clear of infection, the women were randomised to receive prophylactically either one clotrimazole 500 mg vaginal tablet or an identical placebo tablet (prophylaxis regimen A). In both cases, one tablet was to be used each month, one week before the expected onset ofmenstruation, as symptoms most often recur at that time. The women were requested to return to the clinics for examination each month, two weeks after using their medication. Symptoms (discharge, itching, and burning) and clinical signs (discharge, vulvitis, and vaginitis) were recorded at each visit, and specimens were taken for mycological investigation.
If, during the 12 month period of prophylaxis, a woman developed symptoms or clinical signs of candidosis, she was temporarily withdrawn from the trial and given further active treatment with six clotrimazole 100 mg vaginal tablets. Once clear of infection, patients who were willing to continue with the trial were given one clotrimazole 500 mg vaginal tablet a month for up to 12 months (prophylaxis regimen B). As with regimen A, this treatment was administered one week before menstruation, and the woman was instructed to return for examination two weeks later.
Patients who developed symptoms or clinical signs of candidosis during that 12 month period of prophylaxis were again withdrawn from the trial and given further active treatment. Once clear ofinfection, those who wished to continue were given two clotrimazole 500 mg vaginal tablets as prophylaxis each month (regimen C). The first was to be used one week before menstruation and the second at the end of menstruation. Each women was assessed at monthly intervals, about two weeks after the second tablet had been used.
The results were analysed with a rank correlation method.3
Results
We admitted to prophylaxis regimen A 42 women aged between 18 and 45. All had presented with C albicans infection. We assigned 21 to the active prophylaxis group and the remaining 21 to the placebo group. The composition of these groups was similar regarding age, contraceptive method, and number of episodes of candidosis during the preceding year ( to further prophylaxis and were admitted to regimen B (once monthly active prophylaxis). Four of these women subsequently defaulted, however, and have been excluded from analysis. Of 21 women receiving regimen B who relapsed and required further treatment, 19 consented to further twice monthly prophylaxis (regimen C). Two ofthese women subsequently defaulted, however, and have been excluded from the results. Figure 1 shows the cumulative total percentages of women who developed symptoms or clinical signs while receiving the different prophylaxis regimens. Of the 21 women who received placebo treatment, no fewer than 16 (76%) developed symptoms or signs within three months, and only one remained clear for 12 months. Nine (53%) ofthe 17 women given regimen A active treatment developed symptoms or signs within three months, as did 13 (43%) of the 30 women receiving regimen B. Three (18%) of the 17 women given regimen A active treatment and nine (30%) of This was significantly (p < 0.05) better than the effect of placebo treatment. Figure 2 shows the cumulative total percentages of women who became recolonised (all with C albicans) while receiving the different prophylaxis regimens. No appreciable difference was seen between the different regimens; over half the women in all groups had become recolonised within three months, and at 12 months over 85% were colonised.
Discussion
The prevention of recurrent vaginal candidosis remains a difficult problem, and until we can address the underlying cause(s) of the condition optimum management with antifungals is required. Women with vaginal candidosis often respond to local antifungal treatment, but symptoms then recur within a few weeks. Indeed, 16 (76%) out of 21 women given placebo treatment in this investigation suffered a symptomatic recurrence within two months. Symptoms also recur despite more prolonged local treatment or concomitant treatment of the intestinal tract4 or sexual partner. 5 Davidson and Mould were the first to report the beneficial effect of intermittent local antifungal prophylaxis in women with recurrent candidosis.6 Application ofclotrimazole vaginal tablets and cream for six consecutive nights during each menstrual cycle, commencing on the fifth night of the cycle, caused an appreciable reduction in the incidence of symptomatic recurrences; 11 % of women given active treatment relapsed within four months compared with 53% given identical placebo treatment. More recently, Sobel In conclusion, intermittent local prophylaxis with single dose clotrimazole vaginal tablets has been shown to reduce the recurrence of symptoms in women with recurrent vaginal candidosis. Application oftwo 500 mg doses ofclotrimazole a month produced prolonged symptomatic relief in most women, though it often failed to prevent reacquisition of C albicans. More frequent prophylactic treatment might benefit the women who relapsed while receiving this regimen.
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